Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 4Phase 3 2Phase 1 2Phase 4 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 7Prostatic Neoplasms 6Papillomavirus Infections 6Neoplasms 6Polycystic Ovary Syndrome 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Tuberous Sclerosis 2Thyroid Neoplasms 2Stomach Neoplasms 2Smoking Cessation 2Sarcoma 2Rectal Neoplasms 2Pancreatic Neoplasms 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Hematologic Neoplasms 2Head and Neck Neoplasms 2Graft vs Host Disease 2Dupuytren Contracture 2Diabetes Mellitus 2Dementia 2Cardiovascular Diseases 2Carcinoma, Hepatocellular 2Wrist Fractures 1Vaccine-Preventable Diseases 1Uterine Cervical Neoplasms 1Tobacco Use Cessation 1Thyroid Diseases 1Thalassemia 1

Interventions

olaparib 1enzalutamide 1Prednisone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Active not recruiting × Metastatic Castration-resistant Prostate Cancer × Clear all
NCT05457257 2026-04-21

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

AstraZeneca

Phase 4 Active not recruiting
43 enrolled 16 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡